U.S. Senator Marco Rubio’s (R-FL) office will host in-person and virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of...
News
Latest News
Rubio Receives Democracy Award for Innovation and Modernization
Every year, the Congressional Management Foundation (CMF) recognizes Members of Congress for their non-legislative achievements in operations, communications, and constituent services. U.S. Senator Marco Rubio (R-FL) was awarded the 2024 Democracy Award for...
Rubio sobre la Toma de Posesión del Presidente Panameño
El senador estadounidense Marco Rubio (R-FL) emitió el siguiente comunicado sobre la toma de posesión del presidente panameño José Mulino: “A principios de este año, tras un proceso electoral pacífico y democrático, el pueblo de Panamá eligió al Presidente José...
Rubio Statement on Panamanian President’s Inauguration
U.S. Senator Marco Rubio (R-FL) issued the following statement regarding the inauguration of Panamanian President José Mulino: “Earlier this year, following a peaceful and democratic electoral process, the people of Panama elected President José Mulino as their new...
Rubio on State Department’s 2023 International Religious Freedom Report
Each year, the U.S. Department of State releases to Congress its International Religious Freedom Report. This report highlights the status of religious freedom in countries worldwide. U.S. Senator Marco Rubio (R-FL) issued the following statement regarding the release...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host in-person and virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of...
Rubio, Coons Introduce Legislation to Improve Domestic Biopharmaceutical Manufacturing Capabilities for Emerging Public Health Threats
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Chris Coons (D-DE) introduced the Agility in Manufacturing Preparedness Act (S.3553) to require the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for the purpose of evaluating the current capacity and vulnerabilities of biopharmaceutical manufacturing in the United States. NIIMBL is a public-private partnership focused on improving manufacturing capabilities through its cutting-edge expertise, which would help the federal government enhance its preparedness and response capabilities for emerging public health threats. Rubio and Coons first introduced this bill as an amendment (#1917) to the Senate’s Endless Frontier Act in May 2021.
“America needs to be able to make things again, especially medicine,” Rubio said. “My new bill will help bring that back.”
“The current global health crisis has once again underscored the importance of sustained attention to potential threats and our preparedness for them. Expanding our manufacturing capacity in the United States and ensuring that it can respond to a variety of threats is imperative,” Coons said. “The Agility in Manufacturing Preparedness Act will put us in a position to improve our medical preparedness and support America’s health.”
The legislation specifically requires NIIMBL, in partnership with HHS, to:
- Review current domestic biopharmaceutical manufacturing capacity at HHS and its adaptability to various threats;
- Draft recommendations for developing, demonstrating, deploying, and advancing new domestic biopharmaceutical manufacturing technologies that address gaps in HHS’ current capabilities;
- Aligns federal technologies with private-sector capabilities, including those through BARDA’s new BioMAP initiative; and
- Identifies other opportunities and priorities to improve U.S. public health, medical preparedness and response capabilities, and domestic biopharmaceutical manufacturing capabilities.